PPARA and lung cancer: What is more, a clinical trial (UMIN000017854) has even suggested that combining the pan-PPAR agonist bezafibrate with the PD-1 immune checkpoint inhibitor nivolumab could improve treatment outcomes in non–small cell lung cancer [63].